GLP-1 Drugs Don't Work the Same for Everyone — Here's What the Research Actually Shows
Written by Alejandro Reyes
Founder & Lead Researcher
Reviewed by Peptide Nerds Editorial · Updated June 2026
The "GLP-1s Work for Everyone" Myth Is Finally Getting the Research It Deserves
Everyone's talking about Ozempic like it's a universal fix. Take the shot, lose the weight, done.
But a major new systematic review and meta-analysis just dropped some cold water on that idea — and if you're on a GLP-1 drug, or thinking about starting one, what it found should genuinely change how you think about your results.
Important: I'm not a doctor. Everything I share here is based on published research. Talk to your physician before making any changes to your health regimen.
The Bottom Line
- GLP-1 receptor agonists like semaglutide and tirzepatide do produce meaningful weight loss on average — but that average hides enormous individual variation.
- A 2025 systematic review and meta-analysis found significant heterogeneity in weight loss outcomes across studies and within studies — meaning some people lose a lot, some lose a little, and the drug itself isn't the only variable.
- Factors like baseline body weight, diabetes status, biological sex, age, and diet all appear to influence how much weight you actually lose.
- The myth that "GLP-1s work the same for everyone" is not supported by the evidence. The average result you see in headlines may not be your result.
- Actionable takeaway: If you're not seeing results comparable to clinical trial averages, you're not broken — and neither is the drug. Work with your doctor to identify which factors might be influencing your response, rather than assuming the medication "doesn't work."
Wait — Aren't the Clinical Trial Results Pretty Impressive?
They are. No one's disputing that.
Semaglutide (Wegovy) showed average weight loss of around 15% of body weight in the STEP trials. Tirzepatide (Zepbound) pushed that to nearly 21% in the SURMOUNT trials. Those are real, significant numbers backed by rigorous research.
But here's the thing about averages: they can hide a huge range of individual outcomes underneath.
If one person loses 30% of their body weight and another loses 5%, the average between them is 17.5%. Both are counted as a "success" in the data. But those two people had completely different experiences — and possibly completely different biological situations that drove those different results.
That gap between the average and your actual result is what researchers call treatment effect heterogeneity. And according to the latest evidence, it's a much bigger deal with GLP-1 drugs than most people realize.
What This New Research Actually Found
A systematic review and meta-analysis published in 2025 looked specifically at this question: do GLP-1 receptor agonists produce the same results across different types of people, or does your outcome depend heavily on who you are?
The short answer: your outcome depends heavily on who you are.
The researchers analyzed data across multiple GLP-1 trials and found statistically significant heterogeneity — a fancy way of saying the results varied far more than you'd expect if the drug were simply doing the same thing to every body.
This wasn't just variation between different drugs. It was variation within the same drug, across people with different baseline characteristics.
Some people were losing dramatically more weight than the average. Others were seeing minimal results. And the spread wasn't random — certain factors kept showing up as predictors of better or worse outcomes.
The Myth: "If It Works in Trials, It'll Work for You"
This is probably the most common misconception floating around GLP-1 conversations right now.
People read a headline that says "semaglutide users lost an average of 15% body weight" and mentally translate that to: "I should expect to lose 15% of my body weight."
That's not how drug research works — but the way results get reported in mainstream media makes it feel that way.
Clinical trials recruit specific populations. They have inclusion and exclusion criteria. They control for diet and exercise in ways that real-world use doesn't. And even within those controlled conditions, the individual results still vary enormously.
The 15% average is a population-level number. It doesn't tell you where on the distribution you'll land.
So What Actually Predicts Your Response?
This is where it gets genuinely useful. The research points to several factors that appear to influence how much weight you lose on GLP-1 drugs.
Starting Weight and BMI
People with higher baseline body weight tend to lose more total pounds, but the percentage of body weight lost can vary. Where you're starting from matters.
Diabetes Status
Multiple analyses have noted that people with type 2 diabetes tend to lose somewhat less weight on GLP-1s compared to people without diabetes. This has been observed across both semaglutide and tirzepatide trials. The reasons aren't fully understood, but it likely relates to how metabolic dysfunction affects the drug's mechanisms.
Biological Sex
There's emerging data suggesting biological sex may influence response. A 2025 study examining GLP-1 use in the context of joint surgery outcomes flagged that women and men may experience different risk profiles and response patterns. This is an active area of investigation, not a settled conclusion — but it's worth knowing the research is heading there.
Diet Quality During Treatment
A 2026 systematic review specifically looked at nutritional management in people taking GLP-1 and dual GIP/GLP-1 receptor agonists. The finding: dietary strategies during treatment meaningfully influenced outcomes. GLP-1s suppress appetite, but they don't override what you actually put in your body when you do eat.
Protein intake in particular kept coming up as relevant. When you're eating significantly less, the composition of what you're eating matters more, not less.
Gut Microbiome
This one is early-stage, but worth flagging. A 2026 paper in the British Journal of Clinical Pharmacology outlined evidence for a bidirectional relationship between GLP-1 receptor agonists and the gut microbiome. The drug changes the microbiome, and the microbiome may influence how the drug works. Individual microbiome variation could be part of why people respond so differently.
The Muscle Loss Variable Nobody Talks About
Here's another layer to this story that often gets missed.
Weight loss is not the same as fat loss. When you lose weight fast, some of what you're losing is lean mass — including muscle.
A 2026 population-based observational study found that muscle atrophy was associated with GLP-1 receptor agonist use. The amount of lean mass lost varied across individuals — and that variation has real consequences.
Two people might lose the same total number of pounds on a GLP-1. But one might be losing mostly fat while maintaining muscle, and the other might be losing a significant amount of muscle alongside fat. Their scale results look identical. Their actual body composition outcomes are very different.
Real-world evidence published in Diabetes, Metabolic Syndrome and Obesity suggests that oral nutritional supplements — particularly protein-focused ones — may help preserve lean body mass during GLP-1-driven weight loss. But individual variation in this outcome is also significant.
The takeaway: the number on the scale is one metric. It's not the whole story. And it's not the same story for everyone.
Why This Matters Beyond Just Managing Expectations
Understanding that GLP-1 results vary isn't just about not being disappointed.
It's about asking the right questions.
If you've been on semaglutide for three months and you've lost 6% of your body weight instead of the 15% you read about, the instinct is to either blame yourself or conclude the drug doesn't work for you. Both of those conclusions might be wrong.
The research suggests there are real, biological and behavioral factors influencing your response — and some of them can be addressed. Nutrition quality, protein intake, activity level, and even when and how you take the medication may all play a role.
And for some people, a different GLP-1 or a dual-receptor agonist like tirzepatide may produce a significantly better response. A post-hoc analysis of the SURPASS-2 trial found that tirzepatide outperformed semaglutide in achieving specific metabolic targets in type 2 diabetes patients — suggesting the drugs are not interchangeable, and switching may matter for some people.
What This Doesn't Mean
To be clear about what the research is not saying.
It's not saying GLP-1 drugs don't work. The evidence base for meaningful, clinically significant weight loss on these drugs is substantial.
It's not saying you should expect a bad outcome. For many people, results are excellent.
It's saying the population average is not your personal prediction. And that a lack of response should prompt investigation, not resignation.
FAQ
Why do some people lose way more weight on Ozempic than others?
Multiple factors appear to influence response, including starting weight, diabetes status, biological sex, diet quality during treatment, and potentially gut microbiome composition. A 2025 meta-analysis confirmed that treatment effect heterogeneity in GLP-1 drugs is significant — meaning individual variation in outcomes is real and substantial, not just noise.
Does tirzepatide work better than semaglutide for everyone?
No. On average, tirzepatide produces greater weight loss in clinical trials. But "on average" is doing a lot of work there. Some people may respond better to semaglutide, and individual factors influence outcomes on both drugs. A post-hoc analysis of SURPASS-2 found tirzepatide outperformed semaglutide on specific metabolic markers, but head-to-head data for every subgroup is still limited.
Does your diet still matter when you're on a GLP-1?
Yes — significantly. A 2026 systematic review of nutritional management during GLP-1 treatment found that dietary strategies meaningfully influenced outcomes. The drug reduces appetite, but the composition of what you eat still matters, especially protein intake to help preserve muscle mass.
Can GLP-1 drugs cause muscle loss?
Emerging evidence suggests they can. A 2026 population-based study found muscle atrophy associated with GLP-1 use, with variation across individuals. Resistance training and adequate protein intake are the main tools researchers currently point to for mitigating this risk — though individual results vary.
If I'm not seeing results, what should I ask my doctor?
Ask about your specific response predictors: Is your dose optimized? What does your protein intake look like? Are you a candidate for a different drug or formulation? Are there metabolic factors affecting your response? The research is clear that non-response or partial response deserves investigation, not just acceptance.
The Bottom Line on GLP-1 Heterogeneity
The biggest myth in the GLP-1 conversation right now is that these drugs are a one-size-fits-all solution.
They're not. The science is getting clearer on that every month.
What the research actually shows is that GLP-1 receptor agonists are powerful tools — but their effects are shaped by who you are, what you're eating, how your gut works, and factors we don't fully understand yet.
If you're considering a GLP-1 drug, go in with realistic expectations grounded in the research, not in headlines. If you're already on one and not hitting the averages you expected, don't quit — dig in with your doctor to understand why, and explore what variables might be addressable.
The drug works. But how much it works for you is a more complex answer than any headline will give you.
Medical Disclaimer: The information on this website is for educational and informational purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide protocol, medication, or supplement regimen. Individual results vary. The author shares published research — not medical recommendations.
Sources
- Heterogeneity of Treatment Effects of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss in Adults: A Systematic Review and Meta-Analysis — PubMed, 2025
- Dietary Strategies and Nutritional Management in Patients Receiving GLP-1 and Dual GIP/GLP-1 Receptor Agonists as Adjuncts to Lifestyle Interventions: A Systematic Review of Randomised Clinical Trials — Diabetes, Obesity & Metabolism, 2026
- Oral Nutritional Supplements and Body Composition Outcomes Among GLP-1 Receptor Agonist Users: Real-World Evidence — Diabetes, Metabolic Syndrome and Obesity, 2026
- Muscle Atrophy Associated with Glucagon-Like Peptide-1 Receptor Agonists: A Population-Based Observational Study — Clinical Nutrition, 2026
- GLP-1 Agonists and the Gut Microbiome: A Bidirectional Relationship — British Journal of Clinical Pharmacology, 2026
- GLP-1 Receptor Agonist Weight Loss Therapy and Arthroplasty: Are Women at Greater Risk for Complications? — PubMed, 2025
- Efficacy of Tirzepatide Versus Semaglutide in Achieving Therapeutic Targets in Type 2 Diabetes: A Post Hoc Analysis of the SURPASS-2 Trial — PubMed, 2025
Free Peptide Weight Loss Guide
Semaglutide vs. tirzepatide vs. retatrutide. Dosing protocols, side effects, gray market sourcing, and what the clinical trials found.